Andere Sprachen MediWound Ltd.

Aktien

A110TG

IL0011316309

MDWD

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
17.59 ^USD	+7.19%		+0.86%	+72.96%

21.03.	MediWound Ltd. gibt Umsatzprognose für die Jahre 2025 und 2026 ab	CI
21.03.	Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	14:01
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	14:00
MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	21.03.
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M	21.03.
MediWound: Q4 Earnings Snapshot	21.03.
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	21.03.
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21.03.
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	14.03.
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	14.03.
Sector Update: Health Care Stocks Mixed Late Afternoon	12.02.
MediWound Shares Rise After Positive Results From EscharEx Comparison Study	12.02.
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study	12.02.
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study	12.02.
MediWound to Participate in Two Upcoming Investor Conferences	05.02.
MediWound to Participate in Two Upcoming Investor Conferences	05.02.
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA	09.01.
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	09.01.
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	09.01.
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns	09.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MediWound Ltd.

Aktien

A110TG

IL0011316309

MDWD

Andere Sprachen

Filter